Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
New trends in synthetic medicinal chemistry [[electronic resource] /] / edited by Fulvio Gualtieri
| New trends in synthetic medicinal chemistry [[electronic resource] /] / edited by Fulvio Gualtieri |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2000 |
| Descrizione fisica | 1 online resource (372 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | GualtieriF |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Synthesis
Pharmaceutical chemistry |
| ISBN |
1-282-01040-9
9786612010408 3-527-61340-4 3-527-61341-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Methods and Principles in Medicinal Chemistry; Preface; List of Contributors; Contents; 1 Organic Synthesis and Medicinal Chemistry; 2 Series Design in Synthetic Chemistry; 3 Combinatorial Chemistry; 4 Tubes and Cubes. Chips and Tips: Tools for Solid-Phase Organic Synthesis; 5 Stereoselective Synthesis of Enantiomerically Pure Drugs; 6 Resolution of Enantiomers of Chiral Drugs; 7 Biocatalyzed Reactions; 8 Selective Glycosidation Reactions and their Use in Medicinal Chemistry; 9 Chemistry of Antisense Oligonucleotides; Index |
| Record Nr. | UNINA-9910830718303321 |
| Weinheim ; ; New York, : Wiley-VCH, c2000 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
New trends in synthetic medicinal chemistry [[electronic resource] /] / edited by Fulvio Gualtieri
| New trends in synthetic medicinal chemistry [[electronic resource] /] / edited by Fulvio Gualtieri |
| Pubbl/distr/stampa | Weinheim ; ; New York, : Wiley-VCH, c2000 |
| Descrizione fisica | 1 online resource (372 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) | GualtieriF |
| Collana | Methods and principles in medicinal chemistry |
| Soggetto topico |
Drugs - Synthesis
Pharmaceutical chemistry |
| ISBN |
1-282-01040-9
9786612010408 3-527-61340-4 3-527-61341-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Methods and Principles in Medicinal Chemistry; Preface; List of Contributors; Contents; 1 Organic Synthesis and Medicinal Chemistry; 2 Series Design in Synthetic Chemistry; 3 Combinatorial Chemistry; 4 Tubes and Cubes. Chips and Tips: Tools for Solid-Phase Organic Synthesis; 5 Stereoselective Synthesis of Enantiomerically Pure Drugs; 6 Resolution of Enantiomers of Chiral Drugs; 7 Biocatalyzed Reactions; 8 Selective Glycosidation Reactions and their Use in Medicinal Chemistry; 9 Chemistry of Antisense Oligonucleotides; Index |
| Record Nr. | UNINA-9910841235003321 |
| Weinheim ; ; New York, : Wiley-VCH, c2000 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics / / edited by Lisa M. Plitnick, MS, PhD, and Danuta J. Herzyk, PhD, Merck Research Laboratories, Merck & Co., Inc. West Point, PA, USA
| Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics / / edited by Lisa M. Plitnick, MS, PhD, and Danuta J. Herzyk, PhD, Merck Research Laboratories, Merck & Co., Inc. West Point, PA, USA |
| Pubbl/distr/stampa | London, : Academic Press, 2013 |
| Descrizione fisica | 1 online resource (xv, 416 pages, 8 unnumbered pages of plates) : illustrations (some color) |
| Disciplina | 615/.19 |
| Collana | Gale eBooks |
| Soggetto topico |
Biopharmaceutics
Biologicals Biological products |
| ISBN | 0-12-394823-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics; Copyright; Dedication; Contents; Preface; Contributors; Acknowledgments; Section I Development of Biopharmaceuticals Defined as Novel Biologics; Chapter 1 - Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development; INTRODUCTION; HISTORY AND EVOLUTION OF BIOPHARMACEUTICALS; DEVELOPMENT OF DIVERSE BIOPHARMACEUTICAL MODALITIES; COMPARISON OF SMALL-MOLECULE DRUGS TO BIOPHARMACEUTICALS; SUMMARY; References
Chapter 2 - Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological MedicinesINTRODUCTION; SPECIES SELECTION; STUDY DESIGN CONSIDERATIONS FOR REPEAT-DOSE STUDIES; IMMUNOGENICITY; REPRODUCTIVE AND DEVELOPMENTAL TOXICITY; GENOTOXICITY AND CARCINOGENICITY; SPECIAL CONSIDERATIONS FOR ANTICANCER DRUGS; FIRST-IN-HUMAN (FIH) CLINICAL TRIAL; SUMMARY; References; Chapter 3 - Early De-risking Strategy for Novel Biotherapeutics; INTRODUCTION; ESTABLISHING A SAFETY PROFILE FOR BIOTHERAPEUTICS; GENERAL SAFETY CONSIDERATIONS RELATED TO BIOTHERAPEUTICS PROGRESS IN EVALUATION OF IMMUNOTOXICITYCAN WE BETTER ADDRESS POTENTIAL OFF-TARGET TOXICITY?; SUMMARY; References; Chapter 4 - Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics; INTRODUCTION; ABSORPTION, DISTRIBUTION AND ELIMINATION OF BIOPHARMACEUTICALS; DISPOSITION OF MODIFIED MOLECULES; "METABOLISM" AND BIODISTRIBUTION FOR BIOPHARMACEUTICALS; IMMUNOGENICITY AND IMPACTS ON PK AND BIODISTRIBUTION; PHARMACOKINETICS AND PHARMACODYNAMICS; PRECLINICAL TO CLINICAL TRANSLATION; BIOANALYTICS; DRUG ASSAYS; BIOMARKERS: TARGET ENGAGEMENT ASSAYS IMMUNOGENICITY ASSESSMENT: ADA ASSAYSSUMMARY; References; Section II Development of Biosimilars; Chapter 5 - Overview of Biosimilar Therapeutics; INTRODUCTION; THE CONCEPT OF BIOSIMILARS; GENERAL CONSIDERATIONS FOR DEVELOPMENT OF BIOSIMILARS; BIOSIMILAR CANDIDATES BASED ON MODALITY AND THERAPEUTIC CLASS; SUMMARY; References; Chapter 6 - Regulatory Standards for the Approval of Biosimilar Products: A Global Review; INTRODUCTION; EUROPEAN UNION-PIONEER FOR THE FIRST REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS; THE WORLD HEALTH ORGANIZATION GUIDANCE ON BIOSIMILARS REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS IN THE UNITED STATESBIOSIMILAR PATHWAYS IN OTHER REGIONS; SUMMARY; References; Chapter 7 - Early Characterization of Biosimilar Therapeutics; INTRODUCTION; RECOMBINANT INSULINS; RECOMBINANT HUMAN GROWTH HORMONE; RECOMBINANT ERYTHROPOIETINS; RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT INTERFERONS; LOW MOLECULAR WEIGHT HEPARINS; MONOCLONAL ANTIBODIES; OTHER CLASSES; SUMMARY; References; Section III Vaccines; Chapter 8 - Introduction to Vaccines and Adjuvants; INTRODUCTION; THE HISTORY OF VACCINES THE IMPACT OF VACCINES ON HUMAN HEALTH |
| Record Nr. | UNINA-9910779753803321 |
| London, : Academic Press, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics / / edited by Lisa M. Plitnick, MS, PhD, and Danuta J. Herzyk, PhD, Merck Research Laboratories, Merck & Co., Inc. West Point, PA, USA
| Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics / / edited by Lisa M. Plitnick, MS, PhD, and Danuta J. Herzyk, PhD, Merck Research Laboratories, Merck & Co., Inc. West Point, PA, USA |
| Pubbl/distr/stampa | London, : Academic Press, 2013 |
| Descrizione fisica | 1 online resource (xv, 416 pages, 8 unnumbered pages of plates) : illustrations (some color) |
| Disciplina | 615/.19 |
| Collana | Gale eBooks |
| Soggetto topico |
Biopharmaceutics
Biologicals Biological products |
| ISBN | 0-12-394823-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics; Copyright; Dedication; Contents; Preface; Contributors; Acknowledgments; Section I Development of Biopharmaceuticals Defined as Novel Biologics; Chapter 1 - Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development; INTRODUCTION; HISTORY AND EVOLUTION OF BIOPHARMACEUTICALS; DEVELOPMENT OF DIVERSE BIOPHARMACEUTICAL MODALITIES; COMPARISON OF SMALL-MOLECULE DRUGS TO BIOPHARMACEUTICALS; SUMMARY; References
Chapter 2 - Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological MedicinesINTRODUCTION; SPECIES SELECTION; STUDY DESIGN CONSIDERATIONS FOR REPEAT-DOSE STUDIES; IMMUNOGENICITY; REPRODUCTIVE AND DEVELOPMENTAL TOXICITY; GENOTOXICITY AND CARCINOGENICITY; SPECIAL CONSIDERATIONS FOR ANTICANCER DRUGS; FIRST-IN-HUMAN (FIH) CLINICAL TRIAL; SUMMARY; References; Chapter 3 - Early De-risking Strategy for Novel Biotherapeutics; INTRODUCTION; ESTABLISHING A SAFETY PROFILE FOR BIOTHERAPEUTICS; GENERAL SAFETY CONSIDERATIONS RELATED TO BIOTHERAPEUTICS PROGRESS IN EVALUATION OF IMMUNOTOXICITYCAN WE BETTER ADDRESS POTENTIAL OFF-TARGET TOXICITY?; SUMMARY; References; Chapter 4 - Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics; INTRODUCTION; ABSORPTION, DISTRIBUTION AND ELIMINATION OF BIOPHARMACEUTICALS; DISPOSITION OF MODIFIED MOLECULES; "METABOLISM" AND BIODISTRIBUTION FOR BIOPHARMACEUTICALS; IMMUNOGENICITY AND IMPACTS ON PK AND BIODISTRIBUTION; PHARMACOKINETICS AND PHARMACODYNAMICS; PRECLINICAL TO CLINICAL TRANSLATION; BIOANALYTICS; DRUG ASSAYS; BIOMARKERS: TARGET ENGAGEMENT ASSAYS IMMUNOGENICITY ASSESSMENT: ADA ASSAYSSUMMARY; References; Section II Development of Biosimilars; Chapter 5 - Overview of Biosimilar Therapeutics; INTRODUCTION; THE CONCEPT OF BIOSIMILARS; GENERAL CONSIDERATIONS FOR DEVELOPMENT OF BIOSIMILARS; BIOSIMILAR CANDIDATES BASED ON MODALITY AND THERAPEUTIC CLASS; SUMMARY; References; Chapter 6 - Regulatory Standards for the Approval of Biosimilar Products: A Global Review; INTRODUCTION; EUROPEAN UNION-PIONEER FOR THE FIRST REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS; THE WORLD HEALTH ORGANIZATION GUIDANCE ON BIOSIMILARS REGULATORY PATHWAY FOR BIOSIMILAR PRODUCTS IN THE UNITED STATESBIOSIMILAR PATHWAYS IN OTHER REGIONS; SUMMARY; References; Chapter 7 - Early Characterization of Biosimilar Therapeutics; INTRODUCTION; RECOMBINANT INSULINS; RECOMBINANT HUMAN GROWTH HORMONE; RECOMBINANT ERYTHROPOIETINS; RECOMBINANT GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT INTERFERONS; LOW MOLECULAR WEIGHT HEPARINS; MONOCLONAL ANTIBODIES; OTHER CLASSES; SUMMARY; References; Section III Vaccines; Chapter 8 - Introduction to Vaccines and Adjuvants; INTRODUCTION; THE HISTORY OF VACCINES THE IMPACT OF VACCINES ON HUMAN HEALTH |
| Record Nr. | UNINA-9910815087903321 |
| London, : Academic Press, 2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oral bioavailability [[electronic resource] ] : basic principles, advanced concepts, and applications / / edited by Ming Hu, Xiaoling Li
| Oral bioavailability [[electronic resource] ] : basic principles, advanced concepts, and applications / / edited by Ming Hu, Xiaoling Li |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (570 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
HuMing, Ph. D.
LiXiaoling <1957-> |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drugs - Bioavailability
Drug development Intestinal absorption |
| ISBN |
1-283-25776-9
9786613257765 1-118-06758-4 1-118-06759-2 1-118-06752-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ORAL BIOAVAILABILITY; CONTENTS; Foreword; Preface; Contributors; 1 Barriers to Oral Bioavailability-An Overview; 2 Physicochemical Characterization of Pharmaceutical Solids; 3 Solubility of Pharmaceutical Solids; 4 In Vitro Dissolution of Pharmaceutical Solids; 5 Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption; 6 Absorption of Drugs via Passive Diffusion and Carrier-Mediated Pathways; 7 In Vitro-In Vivo Correlations of Pharmaceutical Dosage Forms; 8 Drug Metabolism in Gastrointestinal Tract
9 Efflux of Drugs via Transporters-The Antiabsorption Pathway 10 Liver Drug Metabolism; 11 Protein Binding of Drugs; 12 Urinary Excretion of Drugs and Drug Reabsorption; 13 Pharmacokinetic Behaviors of Orally Administered Drugs; 14 Effects of Food on Drug Absorption; 15 Drug-Drug Interactions and Drug-Dietary Chemical Interactions; 16 Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans; 17 Amino Acid Drug Transporters; 18 Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals 19 Organic Anion and Cation Drug Transporters 20 Gastric Retentive Drug Delivery Systems; 21 Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems; 22 Prodrug Strategies to Enhance Oral Drug Absorption; 23 Oral Delivery of Protein/Peptide Therapeutics; 24 ABC Transporters in Intestinal and Liver Efflux; 25 Interplay Between Efflux Transporters and Metabolic Enzymes; 26 Regulatory Considerations in Metabolism- and Transporter-Based Drug Interactions; 27 Caco-2 Cell Culture Model for Oral Drug Absorption; 28 MDCK Cells and Other Cell-Culture Models of Oral Drug Absorption 29 Intestinal Perfusion Methods for Oral Drug Absorptions 30 Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion; 31 In vivo Methods for Oral Bioavailability Studies; 32 Determination of Regulation of Drug-Metabolizing Enzymes and Transporters; 33 Computational and Pharmacoinformatic Approaches to Oral Bioavailability Prediction; Index |
| Record Nr. | UNINA-9910139611803321 |
| Hoboken, NJ, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oral bioavailability [[electronic resource] ] : basic principles, advanced concepts, and applications / / edited by Ming Hu, Xiaoling Li
| Oral bioavailability [[electronic resource] ] : basic principles, advanced concepts, and applications / / edited by Ming Hu, Xiaoling Li |
| Pubbl/distr/stampa | Hoboken, NJ, : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (570 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
HuMing, Ph. D.
LiXiaoling <1957-> |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drugs - Bioavailability
Drug development Intestinal absorption |
| ISBN |
1-283-25776-9
9786613257765 1-118-06758-4 1-118-06759-2 1-118-06752-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ORAL BIOAVAILABILITY; CONTENTS; Foreword; Preface; Contributors; 1 Barriers to Oral Bioavailability-An Overview; 2 Physicochemical Characterization of Pharmaceutical Solids; 3 Solubility of Pharmaceutical Solids; 4 In Vitro Dissolution of Pharmaceutical Solids; 5 Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption; 6 Absorption of Drugs via Passive Diffusion and Carrier-Mediated Pathways; 7 In Vitro-In Vivo Correlations of Pharmaceutical Dosage Forms; 8 Drug Metabolism in Gastrointestinal Tract
9 Efflux of Drugs via Transporters-The Antiabsorption Pathway 10 Liver Drug Metabolism; 11 Protein Binding of Drugs; 12 Urinary Excretion of Drugs and Drug Reabsorption; 13 Pharmacokinetic Behaviors of Orally Administered Drugs; 14 Effects of Food on Drug Absorption; 15 Drug-Drug Interactions and Drug-Dietary Chemical Interactions; 16 Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, and Humans; 17 Amino Acid Drug Transporters; 18 Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals 19 Organic Anion and Cation Drug Transporters 20 Gastric Retentive Drug Delivery Systems; 21 Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems; 22 Prodrug Strategies to Enhance Oral Drug Absorption; 23 Oral Delivery of Protein/Peptide Therapeutics; 24 ABC Transporters in Intestinal and Liver Efflux; 25 Interplay Between Efflux Transporters and Metabolic Enzymes; 26 Regulatory Considerations in Metabolism- and Transporter-Based Drug Interactions; 27 Caco-2 Cell Culture Model for Oral Drug Absorption; 28 MDCK Cells and Other Cell-Culture Models of Oral Drug Absorption 29 Intestinal Perfusion Methods for Oral Drug Absorptions 30 Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion; 31 In vivo Methods for Oral Bioavailability Studies; 32 Determination of Regulation of Drug-Metabolizing Enzymes and Transporters; 33 Computational and Pharmacoinformatic Approaches to Oral Bioavailability Prediction; Index |
| Record Nr. | UNINA-9910808327803321 |
| Hoboken, NJ, : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Organelle-specific pharmaceutical nanotechnology [[electronic resource] /] / edited by Volkmar Weissig, Gerard G.M. D'Souza
| Organelle-specific pharmaceutical nanotechnology [[electronic resource] /] / edited by Volkmar Weissig, Gerard G.M. D'Souza |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, 2010 |
| Descrizione fisica | 1 online resource (638 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
WeissigVolkmar
D'SouzaGerard G. M |
| Soggetto topico |
Pharmaceutical technology
Nanotechnology Drug targeting |
| ISBN |
1-118-07434-3
1-299-18614-9 0-470-87578-X 0-470-87577-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ORGANELLE-SPECIFIC PHARMACEUTICAL NANOTECHNOLOGY; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: An Introduction to Subcellular Nanomedicine: Current Trends and Future Developments; CHAPTER 2: Delivery of Nanosensors to Measure the Intracellular Environment; CHAPTER 3: Cytoplasmic Diffusion of Dendrimers and Dendriplexes; CHAPTER 4: Endocytosis and Intracellular Trafficking of Quantum Dot-Ligand Bioconjugates; CHAPTER 5: Synthesis of Metal Nanoparticle-Based Intracellular Biosensors and Therapeutic Agents; CHAPTER 6: Subcellular Fate of Nanodelivery Systems
CHAPTER 7: Intracellular Fate of Plasmid DNA PolyplexesCHAPTER 8: Intracellular Traffi cking of Membrane Receptor-Mediated Uptake of Carbon Nanotubes; CHAPTER 9: Real-Time Particle Tracking for Studying Intracellular Transport of Nanotherapeutics; CHAPTER 10: Tracking Intracellular Polymer Localization Via Fluorescence Microscopy; CHAPTER 11: Can QSAR Models Describing Small-Molecule Xenobiotics Give Useful Tips for Predicting Uptake and Localization of Nanoparticles in Living Cells? And If Not, Why Not?; CHAPTER 12: Self-Unpacking Gene Delivery Scaffolds CHAPTER 13: Cellular Trafficking of DendrimersCHAPTER 14: Endolysosomolytically Active pH-Sensitive Polymeric Nanotechnology; CHAPTER 15: Uptake and Intracellular Dynamics of Proteins Internalized by Cell-Penetrating Peptides; CHAPTER 16: Cargo Transport by Teams of Molecular Motors: Basic Mechanisms for Intracellular Drug Delivery; CHAPTER 17: The Potential of Photochemical Internalization (PCI) for the Cytosolic Delivery of Nanomedicines; CHAPTER 18: Peptide-Based Nanocarriers for Intracellular Delivery of Biologically Active Proteins CHAPTER 19: Organelle-Specific Pharmaceutical Nanotechnology: Active Cellular Transport of Submicro- and Nanoscale ParticlesCHAPTER 20: Subcellular Targeting of Virus-Envelope-Coated Nanoparticles; CHAPTER 21: Mitochondria-Targeted Pharmaceutical Nanocarriers; CHAPTER 22: Cell-Penetrating Peptides for Cytosolic Delivery of Biomacromolecules; CHAPTER 23: Therapeutic Nano-object Delivery to Subdomains of Cardiac Myocytes; CHAPTER 24: Design Parameters Modulating Intracellular Drug Delivery: Anchoring to Specific Cellular Epitopes, CarrierGeometry, and Use of Auxiliary Pharmacological Agents CHAPTER 25: Uptake Pathways Dependent Intracellular Trafficking of DNA Carrying Nanodelivery SystemsCHAPTER 26: Cellular Interactions of Plasmon-Resonant Gold Nanorods; CHAPTER 27: Quantum Dot Labeling for Assessment of Intracellular Trafficking of Therapeutically Active Molecules; INDEX |
| Record Nr. | UNINA-9910140835903321 |
| Hoboken, NJ, : Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Organelle-specific pharmaceutical nanotechnology [[electronic resource] /] / edited by Volkmar Weissig, Gerard G.M. D'Souza
| Organelle-specific pharmaceutical nanotechnology [[electronic resource] /] / edited by Volkmar Weissig, Gerard G.M. D'Souza |
| Pubbl/distr/stampa | Hoboken, NJ, : Wiley, 2010 |
| Descrizione fisica | 1 online resource (638 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
WeissigVolkmar
D'SouzaGerard G. M |
| Soggetto topico |
Pharmaceutical technology
Nanotechnology Drug targeting |
| ISBN |
1-118-07434-3
1-299-18614-9 0-470-87578-X 0-470-87577-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ORGANELLE-SPECIFIC PHARMACEUTICAL NANOTECHNOLOGY; CONTENTS; PREFACE; CONTRIBUTORS; CHAPTER 1: An Introduction to Subcellular Nanomedicine: Current Trends and Future Developments; CHAPTER 2: Delivery of Nanosensors to Measure the Intracellular Environment; CHAPTER 3: Cytoplasmic Diffusion of Dendrimers and Dendriplexes; CHAPTER 4: Endocytosis and Intracellular Trafficking of Quantum Dot-Ligand Bioconjugates; CHAPTER 5: Synthesis of Metal Nanoparticle-Based Intracellular Biosensors and Therapeutic Agents; CHAPTER 6: Subcellular Fate of Nanodelivery Systems
CHAPTER 7: Intracellular Fate of Plasmid DNA PolyplexesCHAPTER 8: Intracellular Traffi cking of Membrane Receptor-Mediated Uptake of Carbon Nanotubes; CHAPTER 9: Real-Time Particle Tracking for Studying Intracellular Transport of Nanotherapeutics; CHAPTER 10: Tracking Intracellular Polymer Localization Via Fluorescence Microscopy; CHAPTER 11: Can QSAR Models Describing Small-Molecule Xenobiotics Give Useful Tips for Predicting Uptake and Localization of Nanoparticles in Living Cells? And If Not, Why Not?; CHAPTER 12: Self-Unpacking Gene Delivery Scaffolds CHAPTER 13: Cellular Trafficking of DendrimersCHAPTER 14: Endolysosomolytically Active pH-Sensitive Polymeric Nanotechnology; CHAPTER 15: Uptake and Intracellular Dynamics of Proteins Internalized by Cell-Penetrating Peptides; CHAPTER 16: Cargo Transport by Teams of Molecular Motors: Basic Mechanisms for Intracellular Drug Delivery; CHAPTER 17: The Potential of Photochemical Internalization (PCI) for the Cytosolic Delivery of Nanomedicines; CHAPTER 18: Peptide-Based Nanocarriers for Intracellular Delivery of Biologically Active Proteins CHAPTER 19: Organelle-Specific Pharmaceutical Nanotechnology: Active Cellular Transport of Submicro- and Nanoscale ParticlesCHAPTER 20: Subcellular Targeting of Virus-Envelope-Coated Nanoparticles; CHAPTER 21: Mitochondria-Targeted Pharmaceutical Nanocarriers; CHAPTER 22: Cell-Penetrating Peptides for Cytosolic Delivery of Biomacromolecules; CHAPTER 23: Therapeutic Nano-object Delivery to Subdomains of Cardiac Myocytes; CHAPTER 24: Design Parameters Modulating Intracellular Drug Delivery: Anchoring to Specific Cellular Epitopes, CarrierGeometry, and Use of Auxiliary Pharmacological Agents CHAPTER 25: Uptake Pathways Dependent Intracellular Trafficking of DNA Carrying Nanodelivery SystemsCHAPTER 26: Cellular Interactions of Plasmon-Resonant Gold Nanorods; CHAPTER 27: Quantum Dot Labeling for Assessment of Intracellular Trafficking of Therapeutically Active Molecules; INDEX |
| Record Nr. | UNINA-9910821147803321 |
| Hoboken, NJ, : Wiley, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The organic chemistry of drug synthesis . Volume 7 / / Daniel Lednicer
| The organic chemistry of drug synthesis . Volume 7 / / Daniel Lednicer |
| Pubbl/distr/stampa | Hoboken, N.J. : , : John Wiley & Sons, , 2008 |
| Descrizione fisica | 1 online resource (xiii, 272 pages) : illustrations |
| Disciplina |
547.2
615/.19 |
| Altri autori (Persone) | LednicerDaniel <1929-> |
| Collana | Organic chemistry of drug synthesis |
| Soggetto topico |
Pharmaceutical chemistry
Organic compounds - Synthesis |
| ISBN |
1-281-20373-4
9786611203733 0-470-18067-6 0-470-18066-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS; CONTENTS; Preface; 1 OPEN-CHAIN COMPOUNDS; 1. Peptidomimetic Compounds; A. Antiviral Protease Inhibitors; 1. Human Immunodeficiency Virus; 2. Human Rhinovirus; 2. Miscellaneous Peptidomimetic Compounds; References; 2 ALICYCLIC COMPOUNDS; 1. Monocyclic Compounds; A. Prostaglandins; B. Antiviral Agents; C. Miscellaneous Monocyclic Compounds; 2. Polycyclic Compounds: Steroids; A. 19-Nor Steroids; B. Corticosteroid Related Compounds; 3. Polycyclic Compounds; References; 3 MONOCYCLIC AROMATIC COMPOUNDS; 1. Arylcarbonyl Derivatives; 2. Biphenyls
3. Compounds Related to Aniline 4. Compounds Related to Arylsulfonic Acids; 5. Diarylmethanes; 6. Miscellaneous Monocyclic Aromatic Compounds; References; 4 CARBOCYCLIC COMPOUNDS FUSED TO A BENZENE RING; 1. Indenes; 2. Naphthalenes; 3. Tetrahydronaphthalenes; 4. Other benzofused carbocyclic compounds; References; 5 FIVE-MEMBERED HETEROCYCLES; 1. Compounds with One Heteroatom; 2. Compounds with Two Heteroatoms; A. Oxazole and Isoxazoles; B. Imidazoles and a Pyrrazole; C. Thiazoles; D. Triazoles; E. Tetrazoles; References; 6 SIX-MEMBERED HETEROCYCLES; 1. Compounds with One Heteroatom A. PyridinesB. Reduced Pyridines; C. Miscellaneous; 2. Compounds with Two Heteroatoms; A. Pyrimidines; B. Miscellaneous Six-Membered Heterocycles; References; 7 FIVE-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING; 1. Compounds with One Heteroatom; A. Benzofurans; B. Indoles; C. Indolones; D. Miscellaneous Compounds with One Heteroatom; 2. Five-Membered Rings with Two Heterocyclic Atoms; A. Benzimidazoles; B. Miscellaneous Compounds; References; 8 SIX-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING; 1. Compounds with One Heteroatom; A. Benzopyrans; B. Quinolines and Their Derivatives C. Quinolone Antibacterial Agents 2. Compounds with Two Heteroatoms; A. Benzoxazines; B. Quinazolines; C. Miscellaneous Benzo-Fused Heterocycles; References; 9 BICYCLIC FUSED HETEROCYCLES; 1. Compounds with Five-Membered Rings Fused to Six-Membered Rings; A. Compounds with Two Heteroatoms; B. Compounds with Three Heteroatoms; C. Compounds with Four Heteroatoms; 2. Compounds with Two Fused Six-Membered Rings; 3. Miscellaneous Compounds with Two Fused Heterocyclic Rings: Beta Lactams; References; 10 POLYCYCLIC FUSED HETEROCYCLES; 1. Compounds with Three Fused Rings; 2. Compounds with Four Fused Rings 3. Compounds with Five or More Fused Rings: Camptothecins; References; Subject Index; Cross Index of Biological Activity; Cumulative Index |
| Record Nr. | UNINA-9910144290903321 |
| Hoboken, N.J. : , : John Wiley & Sons, , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The organic chemistry of drug synthesis . Volume 7 / / Daniel Lednicer
| The organic chemistry of drug synthesis . Volume 7 / / Daniel Lednicer |
| Pubbl/distr/stampa | Hoboken, N.J. : , : John Wiley & Sons, , 2008 |
| Descrizione fisica | 1 online resource (xiii, 272 pages) : illustrations |
| Disciplina |
547.2
615/.19 |
| Altri autori (Persone) | LednicerDaniel <1929-> |
| Collana | Organic chemistry of drug synthesis |
| Soggetto topico |
Pharmaceutical chemistry
Organic compounds - Synthesis |
| ISBN |
1-281-20373-4
9786611203733 0-470-18067-6 0-470-18066-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS; CONTENTS; Preface; 1 OPEN-CHAIN COMPOUNDS; 1. Peptidomimetic Compounds; A. Antiviral Protease Inhibitors; 1. Human Immunodeficiency Virus; 2. Human Rhinovirus; 2. Miscellaneous Peptidomimetic Compounds; References; 2 ALICYCLIC COMPOUNDS; 1. Monocyclic Compounds; A. Prostaglandins; B. Antiviral Agents; C. Miscellaneous Monocyclic Compounds; 2. Polycyclic Compounds: Steroids; A. 19-Nor Steroids; B. Corticosteroid Related Compounds; 3. Polycyclic Compounds; References; 3 MONOCYCLIC AROMATIC COMPOUNDS; 1. Arylcarbonyl Derivatives; 2. Biphenyls
3. Compounds Related to Aniline 4. Compounds Related to Arylsulfonic Acids; 5. Diarylmethanes; 6. Miscellaneous Monocyclic Aromatic Compounds; References; 4 CARBOCYCLIC COMPOUNDS FUSED TO A BENZENE RING; 1. Indenes; 2. Naphthalenes; 3. Tetrahydronaphthalenes; 4. Other benzofused carbocyclic compounds; References; 5 FIVE-MEMBERED HETEROCYCLES; 1. Compounds with One Heteroatom; 2. Compounds with Two Heteroatoms; A. Oxazole and Isoxazoles; B. Imidazoles and a Pyrrazole; C. Thiazoles; D. Triazoles; E. Tetrazoles; References; 6 SIX-MEMBERED HETEROCYCLES; 1. Compounds with One Heteroatom A. PyridinesB. Reduced Pyridines; C. Miscellaneous; 2. Compounds with Two Heteroatoms; A. Pyrimidines; B. Miscellaneous Six-Membered Heterocycles; References; 7 FIVE-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING; 1. Compounds with One Heteroatom; A. Benzofurans; B. Indoles; C. Indolones; D. Miscellaneous Compounds with One Heteroatom; 2. Five-Membered Rings with Two Heterocyclic Atoms; A. Benzimidazoles; B. Miscellaneous Compounds; References; 8 SIX-MEMBERED HETEROCYCLES FUSED TO ONE BENZENE RING; 1. Compounds with One Heteroatom; A. Benzopyrans; B. Quinolines and Their Derivatives C. Quinolone Antibacterial Agents 2. Compounds with Two Heteroatoms; A. Benzoxazines; B. Quinazolines; C. Miscellaneous Benzo-Fused Heterocycles; References; 9 BICYCLIC FUSED HETEROCYCLES; 1. Compounds with Five-Membered Rings Fused to Six-Membered Rings; A. Compounds with Two Heteroatoms; B. Compounds with Three Heteroatoms; C. Compounds with Four Heteroatoms; 2. Compounds with Two Fused Six-Membered Rings; 3. Miscellaneous Compounds with Two Fused Heterocyclic Rings: Beta Lactams; References; 10 POLYCYCLIC FUSED HETEROCYCLES; 1. Compounds with Three Fused Rings; 2. Compounds with Four Fused Rings 3. Compounds with Five or More Fused Rings: Camptothecins; References; Subject Index; Cross Index of Biological Activity; Cumulative Index |
| Record Nr. | UNINA-9910818385103321 |
| Hoboken, N.J. : , : John Wiley & Sons, , 2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
